<p><strong>安斯泰萊製藥 (ADR)</strong> (TSE:4503) 的股東們可能感到有些失望，因為在其最新年度業績發佈後的一個星期內，股價下跌了 7.8%，降至 JP¥2,306。JP¥2.1 萬億的收入與預期一致，儘管法定每股收益（EPS）為 JP¥163，低於預期，差距為 4.8%。對於投資者來説，這是一個重要的時刻，因為他們可以在報告中跟蹤公司的表現，查看專家對明年的預測，並觀察業務預期是否有所變化。因此，我們收集了最新的財報後預測，以瞭解估計值對明年的展望。</p>
<p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
<p>考慮到最新的業績，安斯泰萊製藥的十二位分析師的共識預測是 2027 年的收入為 JP¥2.24 萬億。這反映出與過去 12 個月相比，收入有温和的 4.5% 的改善。每股收益預計將增長 13%，達到 JP¥184。在這份報告發布之前，分析師們曾預測 2027 年的收入為 JP¥2.22 萬億，每股收益（EPS）為 JP¥192。因此，近期業績後，整體情緒似乎略有下降——收入預期沒有重大變化，但分析師們對每股收益的預測進行了小幅下調。</p>
<p>查看我們對安斯泰萊製藥的最新分析</p>
<p>可能令人驚訝的是，分析師們的共識目標價基本保持不變，為 JP¥2,418，顯然暗示預期的收益下降不會對估值產生太大影響。不過，還有另一種看待目標價的方法，那就是查看分析師提出的目標價範圍，因為廣泛的估計範圍可能表明對業務可能結果的多樣化看法。對安斯泰萊製藥的看法存在一些差異，最樂觀的分析師將其估值為 JP¥2,950，而最悲觀的則為每股 JP¥1,600。正如你所看到的，分析師們對該股票的未來並不完全一致，但估計範圍仍然相對狹窄，這可能表明結果並非完全不可預測。</p>
<p>這些估計很有趣，但在比較預測時，考慮安斯泰萊製藥的過去表現以及同行業的公司時，描繪一些更廣泛的趨勢是有用的。我們要強調的是，安斯泰萊製藥的收入增長預計將放緩，預計到 2027 年底的年化增長率為 4.5%，遠低於過去五年 11% 的歷史年增長率。與該行業中 41 家有分析師覆蓋的公司相比，預計它們的收入年增長率為 4.1%。考慮到增長放緩的預測，安斯泰萊製藥的增長率預計與更廣泛的行業大致相同。</p>
<h2>結論</h2>
<p>最重要的是，分析師們下調了他們的每股收益預測，顯示出在這些業績發佈後情緒明顯下降。他們還重新確認了收入預測，預計公司將以與更廣泛行業相似的速度增長。共識目標價沒有實質性變化，表明最新的估計並未對業務的內在價值產生重大影響。</p>
<p>考慮到這一點，我們不應過快得出關於安斯泰萊製藥的結論。長期的盈利能力遠比明年的利潤更為重要。在 Simply Wall St，我們有安斯泰萊製藥到 2029 年的完整分析師估計，你可以在我們的平台上免費查看。</p>
<p>不過，你應該始終考慮風險。舉個例子，我們發現了 <strong>1 個安斯泰萊製藥的警示信號</strong>，你應該注意。</p>

安斯泰萊制藥(ADR)

4503

<p>安斯泰萊製藥 (ADR)（東京證券交易所代碼：4503）公佈了年度財報，股價下跌 7.8%，至 2,306 日元。收入達到預期，為 2.1 萬億日元，但每股收益（EPS）未達標，為 163 日元，低於預期 4.8%。分析師預測 2027 年的收入為 2.24 萬億日元，反映出 4.5% 的增長，而每股收益預計將增長 13%，達到 184 日元。儘管每股收益的預期被下調，但共識目標價仍保持在 2,418 日元。安斯泰萊製藥的增長預計將與行業趨勢保持一致，但分析師對該股票的未來看法各異</p>

<p><strong>Astellas Pharma Inc.</strong> (TSE:4503) shareholders are probably feeling a little disappointed, since its shares fell 7.8% to JP¥2,306 in the week after its latest yearly results. Revenues of JP¥2.1t were in line with forecasts, although statutory earnings per share (EPS) came in below expectations at JP¥163, missing estimates by 4.8%. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.</p>
<div class="lb-trans"><p><strong>安斯泰萊製藥 (ADR)</strong> (TSE:4503) 的股東們可能感到有些失望，因為在其最新年度業績發佈後的一個星期內，股價下跌了 7.8%，降至 JP¥2,306。JP¥2.1 萬億的收入與預期一致，儘管法定每股收益（EPS）為 JP¥163，低於預期，差距為 4.8%。對於投資者來説，這是一個重要的時刻，因為他們可以在報告中跟蹤公司的表現，查看專家對明年的預測，並觀察業務預期是否有所變化。因此，我們收集了最新的財報後預測，以瞭解估計值對明年的展望。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
</div><p>Taking into account the latest results, the consensus forecast from Astellas Pharma's twelve analysts is for revenues of JP¥2.24t in 2027. This reflects a modest 4.5% improvement in revenue compared to the last 12 months. Per-share earnings are expected to expand 13% to JP¥184. In the lead-up to this report, the analysts had been modelling revenues of JP¥2.22t and earnings per share (EPS) of JP¥192 in 2027. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a minor downgrade to their earnings per share forecasts.</p>
<div class="lb-trans"><p>考慮到最新的業績，安斯泰萊製藥的十二位分析師的共識預測是 2027 年的收入為 JP¥2.24 萬億。這反映出與過去 12 個月相比，收入有温和的 4.5% 的改善。每股收益預計將增長 13%，達到 JP¥184。在這份報告發布之前，分析師們曾預測 2027 年的收入為 JP¥2.22 萬億，每股收益（EPS）為 JP¥192。因此，近期業績後，整體情緒似乎略有下降——收入預期沒有重大變化，但分析師們對每股收益的預測進行了小幅下調。</p>
</div><p>View our latest analysis for Astellas Pharma</p>
<div class="lb-trans"><p>查看我們對安斯泰萊製藥的最新分析</p>
</div><p>It might be a surprise to learn that the consensus price target was broadly unchanged at JP¥2,418, with the analysts clearly implying that the forecast decline in earnings is not expected to have much of an impact on valuation. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Astellas Pharma, with the most bullish analyst valuing it at JP¥2,950 and the most bearish at JP¥1,600 per share. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.</p>
<div class="lb-trans"><p>可能令人驚訝的是，分析師們的共識目標價基本保持不變，為 JP¥2,418，顯然暗示預期的收益下降不會對估值產生太大影響。不過，還有另一種看待目標價的方法，那就是查看分析師提出的目標價範圍，因為廣泛的估計範圍可能表明對業務可能結果的多樣化看法。對安斯泰萊製藥的看法存在一些差異，最樂觀的分析師將其估值為 JP¥2,950，而最悲觀的則為每股 JP¥1,600。正如你所看到的，分析師們對該股票的未來並不完全一致，但估計範圍仍然相對狹窄，這可能表明結果並非完全不可預測。</p>
</div><p>These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Astellas Pharma's past performance and to peers in the same industry. We would highlight that Astellas Pharma's revenue growth is expected to slow, with the forecast 4.5% annualised growth rate until the end of 2027 being well below the historical 11% p.a. growth over the last five years. Compare this to the 41 other companies in this industry with analyst coverage, which are forecast to grow their revenue at 4.1% per year. Factoring in the forecast slowdown in growth, it looks like Astellas Pharma is forecast to grow at about the same rate as the wider industry.</p>
<div class="lb-trans"><p>這些估計很有趣，但在比較預測時，考慮安斯泰萊製藥的過去表現以及同行業的公司時，描繪一些更廣泛的趨勢是有用的。我們要強調的是，安斯泰萊製藥的收入增長預計將放緩，預計到 2027 年底的年化增長率為 4.5%，遠低於過去五年 11% 的歷史年增長率。與該行業中 41 家有分析師覆蓋的公司相比，預計它們的收入年增長率為 4.1%。考慮到增長放緩的預測，安斯泰萊製藥的增長率預計與更廣泛的行業大致相同。</p>
</div><h2>The Bottom Line</h2>
<div class="lb-trans"><h2>結論</h2>
</div><p>The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.</p>
<div class="lb-trans"><p>最重要的是，分析師們下調了他們的每股收益預測，顯示出在這些業績發佈後情緒明顯下降。他們還重新確認了收入預測，預計公司將以與更廣泛行業相似的速度增長。共識目標價沒有實質性變化，表明最新的估計並未對業務的內在價值產生重大影響。</p>
</div><p>With that in mind, we wouldn't be too quick to come to a conclusion on Astellas Pharma. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Astellas Pharma going out to 2029, and you can see them free on our platform here..</p>
<div class="lb-trans"><p>考慮到這一點，我們不應過快得出關於安斯泰萊製藥的結論。長期的盈利能力遠比明年的利潤更為重要。在 Simply Wall St，我們有安斯泰萊製藥到 2029 年的完整分析師估計，你可以在我們的平台上免費查看。</p>
</div><p>You should always think about risks though. Case in point, we've spotted <strong>1 warning sign for Astellas Pharma</strong> you should be aware of.</p>
<div class="lb-trans"><p>不過，你應該始終考慮風險。舉個例子，我們發現了 <strong>1 個安斯泰萊製藥的警示信號</strong>，你應該注意。</p>
</div>

安斯泰萊製藥 (ADR)（TSE:4503）剛剛公佈了年度財報：分析師對該股票的看法是否有所改變？